After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.

The RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim, Sanofi, Bayer, Francis Crick Institute, PhoreMost, Allinky Biopharma, Elicio Therapeutics, Oblique Therapeutics, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up, what will be discussed, pricing and ticket options: https://ter.li/8qb2rr.